JP6625045B2 - 相同組換え欠損を評価するための方法および材料 - Google Patents

相同組換え欠損を評価するための方法および材料

Info

Publication number
JP6625045B2
JP6625045B2 JP2016506657A JP2016506657A JP6625045B2 JP 6625045 B2 JP6625045 B2 JP 6625045B2 JP 2016506657 A JP2016506657 A JP 2016506657A JP 2016506657 A JP2016506657 A JP 2016506657A JP 6625045 B2 JP6625045 B2 JP 6625045B2
Authority
JP
Japan
Prior art keywords
region
indicator
pairs
loh
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016506657A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016523511A (ja
JP2016523511A5 (cg-RX-API-DMAC7.html
Inventor
ビクター アブケビック
ビクター アブケビック
キルスティン ティムズ
キルスティン ティムズ
アレクサンダー グティン
アレクサンダー グティン
Original Assignee
ミリアド・ジェネティックス・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51659359&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6625045(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ミリアド・ジェネティックス・インコーポレイテッド filed Critical ミリアド・ジェネティックス・インコーポレイテッド
Publication of JP2016523511A publication Critical patent/JP2016523511A/ja
Publication of JP2016523511A5 publication Critical patent/JP2016523511A5/ja
Priority to JP2019085187A priority Critical patent/JP7522539B2/ja
Application granted granted Critical
Publication of JP6625045B2 publication Critical patent/JP6625045B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6858—Allele-specific amplification
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Medical Informatics (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
JP2016506657A 2013-04-05 2014-04-04 相同組換え欠損を評価するための方法および材料 Active JP6625045B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2019085187A JP7522539B2 (ja) 2013-04-05 2019-04-26 相同組換え欠損を評価するための方法および材料

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361809105P 2013-04-05 2013-04-05
US61/809,105 2013-04-05
US201361913762P 2013-12-09 2013-12-09
US61/913,762 2013-12-09
PCT/US2014/033014 WO2014165785A2 (en) 2013-04-05 2014-04-04 Methods and materials for assessing homologous recombination deficiency

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019085187A Division JP7522539B2 (ja) 2013-04-05 2019-04-26 相同組換え欠損を評価するための方法および材料

Publications (3)

Publication Number Publication Date
JP2016523511A JP2016523511A (ja) 2016-08-12
JP2016523511A5 JP2016523511A5 (cg-RX-API-DMAC7.html) 2017-03-16
JP6625045B2 true JP6625045B2 (ja) 2019-12-25

Family

ID=51659359

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2016506657A Active JP6625045B2 (ja) 2013-04-05 2014-04-04 相同組換え欠損を評価するための方法および材料
JP2019085187A Active JP7522539B2 (ja) 2013-04-05 2019-04-26 相同組換え欠損を評価するための方法および材料
JP2020194936A Active JP7522643B2 (ja) 2013-04-05 2020-11-25 相同組換え欠損を評価するための方法および材料
JP2022169085A Active JP7641938B2 (ja) 2013-04-05 2022-10-21 相同組換え欠損を評価するための方法および材料
JP2025027653A Pending JP2025090619A (ja) 2013-04-05 2025-02-25 相同組換え欠損を評価するための方法および材料

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2019085187A Active JP7522539B2 (ja) 2013-04-05 2019-04-26 相同組換え欠損を評価するための方法および材料
JP2020194936A Active JP7522643B2 (ja) 2013-04-05 2020-11-25 相同組換え欠損を評価するための方法および材料
JP2022169085A Active JP7641938B2 (ja) 2013-04-05 2022-10-21 相同組換え欠損を評価するための方法および材料
JP2025027653A Pending JP2025090619A (ja) 2013-04-05 2025-02-25 相同組換え欠損を評価するための方法および材料

Country Status (9)

Country Link
US (4) US20140363521A1 (cg-RX-API-DMAC7.html)
EP (2) EP2981624B1 (cg-RX-API-DMAC7.html)
JP (5) JP6625045B2 (cg-RX-API-DMAC7.html)
AU (3) AU2014248007B2 (cg-RX-API-DMAC7.html)
CA (1) CA2908745C (cg-RX-API-DMAC7.html)
DK (1) DK2981624T3 (cg-RX-API-DMAC7.html)
ES (1) ES2777228T3 (cg-RX-API-DMAC7.html)
PT (1) PT2981624T (cg-RX-API-DMAC7.html)
WO (1) WO2014165785A2 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019165731A (ja) * 2013-04-05 2019-10-03 ミリアド・ジェネティックス・インコーポレイテッド 相同組換え欠損を評価するための方法および材料

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012027224A1 (en) 2010-08-24 2012-03-01 Dana-Farber Cancer Institute, Inc. Methods for predicting anti-cancer response
EP3225697A3 (en) 2010-12-30 2017-11-22 Foundation Medicine, Inc. Optimization of multigene analysis of tumor samples
WO2012174378A2 (en) 2011-06-17 2012-12-20 Myriad Genetics, Inc. Methods and materials for assessing allelic imbalance
CN107267598B (zh) 2011-12-21 2022-03-25 美瑞德生物工程公司 用于评估杂合性丢失的方法与材料
EP3415915B1 (en) 2012-02-23 2024-10-23 Children's Medical Center Corporation Methods for predicting response to parp inhibitors
CA3126823C (en) 2012-06-07 2023-04-04 Institut Curie Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors
EP3080292B1 (en) 2013-12-09 2022-02-02 Institut Curie Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors
US10545151B2 (en) 2014-02-21 2020-01-28 Epic Sciences, Inc. Methods for analyzing rare circulating cells
ES2946251T3 (es) 2014-08-15 2023-07-14 Myriad Genetics Inc Métodos y materiales para evaluar la deficiencia de recombinación homóloga
CA2967447C (en) * 2014-12-05 2025-07-08 Foundation Medicine, Inc. MULTIGEN ANALYSIS OF TUMOR SAMPLES
EP3230472A4 (en) * 2014-12-08 2018-06-13 Myriad Genetics, Inc. Methods and materials for predicting response to niraparib
WO2016185406A1 (en) 2015-05-19 2016-11-24 Nadathur Estates Pvt. Ltd. Method for identification of a deficient brca1 function
JP7043412B2 (ja) 2015-11-03 2022-03-29 エピック サイエンシス， インコーポレイテッド 疾患の不均一性を特徴づけるための転移性疾患における、循環腫瘍細胞（ｃｔｃ）の単一細胞ゲノムプロファイリング
WO2017106365A1 (en) * 2015-12-14 2017-06-22 Myriad Genetics, Inc. Methods for measuring mutation load
WO2017120324A1 (en) * 2016-01-06 2017-07-13 Epic Sciences, Inc. Single cell genomic profiling of circulating tumor cells (ctcs) in metastatic disease to characterize disease heterogeneity
WO2017165270A1 (en) * 2016-03-21 2017-09-28 Myriad Genetics, Inc. Homologous recombination deficiency to predict neoadjuvant chemotherapy necessity in bladder cancer
WO2017178509A1 (en) 2016-04-12 2017-10-19 Xentech Methods for predicting sensibility to treatment with parp inhibitors in cancerous patients
WO2017191076A1 (en) 2016-05-01 2017-11-09 Genome Research Limited Method of characterising a dna sample
JP7224185B2 (ja) * 2016-05-01 2023-02-17 ゲノム・リサーチ・リミテッド Ｄｎａサンプルを特徴付ける方法
GB2555765A (en) 2016-05-01 2018-05-16 Genome Res Ltd Method of detecting a mutational signature in a sample
KR20230042136A (ko) * 2016-06-29 2023-03-27 테사로, 인코포레이티드 난소암의 치료 방법
KR20210035167A (ko) 2018-06-11 2021-03-31 파운데이션 메디신 인코포레이티드 게놈 변경을 평가하기 위한 조성물 및 방법
JPWO2020137076A1 (ja) * 2018-12-28 2021-11-11 国立大学法人 東京大学 Ｐａｒｐ阻害剤に対する癌の感受性の予測方法および相同組換修復不全を有する癌の検出方法
JP7368483B2 (ja) 2019-02-12 2023-10-24 テンパス ラブズ，インコーポレイテッド 相同組換え欠損を推定するための統合された機械学習フレームワーク
EP4073805B1 (en) 2019-12-10 2024-07-17 Tempus AI, Inc. Systems and methods for predicting homologous recombination deficiency status of a specimen
JP2023506084A (ja) * 2019-12-16 2023-02-14 アジレント・テクノロジーズ・インク ゲノム瘢痕アッセイ及び関連する方法
EP3945525A1 (en) 2020-07-27 2022-02-02 Sophia Genetics S.A. Methods for identifying chromosomal spatial instability such as homologous repair deficiency in low coverage next-generation sequencing data
CN111883211B (zh) * 2020-08-07 2021-04-23 张哲� 一种表征hrd同源重组修复缺陷的基因瘢痕及鉴定方法
US11718869B2 (en) * 2020-08-12 2023-08-08 Zhenyue Biotechnology Jiangsu Co., Ltd. Method and kit for determining genome instability based on next generation sequencing (NGS)
CN112410423B (zh) * 2020-11-03 2021-08-13 南京世和基因生物技术股份有限公司 同源重组缺失的标志物、检测方法以及检测系统
EP4274908A1 (en) * 2021-01-10 2023-11-15 Act Genomics (IP) Limited Homologous recombination deficiency determining method and kit thereof
BE1029144B1 (fr) 2021-02-25 2022-09-20 Oncodna Méthode de caracterisation d'une tumeur à l'aide d'un séquençage ciblé
CN112820351A (zh) * 2021-03-01 2021-05-18 江苏医联生物科技有限公司 检测肿瘤患者的突变和hrd评分指导用药的方法
EP4360094A4 (en) * 2021-06-25 2025-04-23 Foundation Medicine, Inc. SYSTEM AND METHOD FOR CLASSIFYING AN APPROVED REPAIR DEFICIENCY
AR127880A1 (es) * 2021-12-08 2024-03-06 Myriad Genetics Inc Métodos y materiales para evaluar la deficiencia de recombinación homóloga en subtipos de cáncer de mama
KR102523938B1 (ko) * 2022-02-04 2023-04-19 가톨릭대학교 산학협력단 상동 재조합 결핍증 예측 모델의 모델링 방법
EP4605937A1 (en) 2022-10-19 2025-08-27 Vib Vzw Method of determining loss of heterozygosity status of a tumor
WO2025078387A1 (en) 2023-10-10 2025-04-17 Vib Vzw Method of detecting loss of heterozygosity status of a tumor
WO2025078404A1 (en) 2023-10-10 2025-04-17 Vib Vzw Methods of determining response of a tumor to dna-damaging agents or to agents inhibiting or impairing dna repair

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU33730B (en) 1967-04-18 1978-02-28 Farmaceutici Italia Process for preparing a novel antibiotic substance and salts thereof
GB1432562A (en) 1972-04-10 1976-04-22 Rustenburg Platinum Mines Ltd Platinum co-ordination compounds
GB1432563A (en) 1972-04-10 1976-04-22 Rustenburg Platinum Mines Ltd Platinum- co-ordination compounds
ES444380A1 (es) 1976-01-16 1977-06-16 Gosalvez Mario Un procedimiento para preparar derivados metalicos antraci- clinicos.
US4950738A (en) 1984-09-13 1990-08-21 Cytogen Corporation Amine derivatives of anthracycline antibiotics
US5977082A (en) 1985-08-02 1999-11-02 Pharmacia & Upjohn Company Injectable ready-to-use solutions containing an antitumor anthracycline glycoside
US5177075A (en) 1988-08-19 1993-01-05 Warner-Lambert Company Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process
US5295944A (en) 1991-05-14 1994-03-22 Dana-Farber Cancer Institute Method for treating a tumor with ionizing radiation
NZ245112A (en) 1991-11-15 1995-07-26 Smithkline Beecham Corp Pharmaceutical composition comprising a camptothecin analog and a platinum coordination compound
GB9806324D0 (en) 1998-03-24 1998-05-20 Pharmacia & Upjohn Spa Antitumour synergetic composition
ATE478664T1 (de) 2000-12-01 2010-09-15 Eisai Inc Azaphenanthridone-derivate und deren verwendung als parp-inhibitoren
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
US7754684B2 (en) 2003-06-11 2010-07-13 Access Pharmaceuticals, Inc. Macromolecular platinum chelates
US7485707B2 (en) 2003-07-02 2009-02-03 Solux Corporation Thermally stable crystalline epirubicin hydrochloride and method of making the same
ATE454893T1 (de) 2003-07-25 2010-01-15 Cancer Rec Tech Ltd Tricyclische parp-hemmer
WO2005016946A2 (en) 2003-08-13 2005-02-24 University Of South Florida Platinum complexes for the treatment of tumors
CN101495459A (zh) 2005-06-30 2009-07-29 比奥纽默里克药物公司 单吡咯配体铂类似物
KR100925337B1 (ko) * 2009-05-25 2009-11-09 주식회사 마크로젠 염색체 수 이상 검출을 통한 유방암 약물 반응성 예측
DK3327148T3 (da) 2010-06-18 2021-04-12 Myriad Genetics Inc Fremgangsmåder til forudsigelse af status for brca1- og brca2-gener i en cancercelle
WO2012027224A1 (en) * 2010-08-24 2012-03-01 Dana-Farber Cancer Institute, Inc. Methods for predicting anti-cancer response
EP3415915B1 (en) * 2012-02-23 2024-10-23 Children's Medical Center Corporation Methods for predicting response to parp inhibitors
EP2981624B1 (en) * 2013-04-05 2019-12-18 Myriad Genetics, Inc. Methods for assessing homologous recombination deficiency and predicting response to cancer treatment

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019165731A (ja) * 2013-04-05 2019-10-03 ミリアド・ジェネティックス・インコーポレイテッド 相同組換え欠損を評価するための方法および材料

Also Published As

Publication number Publication date
EP3693475A1 (en) 2020-08-12
ES2777228T3 (es) 2020-08-04
JP7641938B2 (ja) 2025-03-07
EP2981624A2 (en) 2016-02-10
JP7522643B2 (ja) 2024-07-25
AU2014248007A1 (en) 2015-10-15
US20180030544A1 (en) 2018-02-01
EP2981624A4 (en) 2016-11-30
NZ712663A (en) 2021-07-30
JP2019165731A (ja) 2019-10-03
US20250223655A1 (en) 2025-07-10
AU2020204028B2 (en) 2022-08-18
CA2908745C (en) 2023-03-14
DK2981624T3 (da) 2020-03-02
JP2016523511A (ja) 2016-08-12
AU2014248007B2 (en) 2020-03-26
AU2020204028A1 (en) 2020-07-09
US20210310079A1 (en) 2021-10-07
EP2981624B1 (en) 2019-12-18
US20140363521A1 (en) 2014-12-11
JP2025090619A (ja) 2025-06-17
JP7522539B2 (ja) 2024-07-25
PT2981624T (pt) 2020-03-23
WO2014165785A2 (en) 2014-10-09
AU2022211880B2 (en) 2025-05-29
AU2022211880A1 (en) 2022-09-01
JP2021036903A (ja) 2021-03-11
CA2908745A1 (en) 2014-10-09
JP2023012488A (ja) 2023-01-25

Similar Documents

Publication Publication Date Title
JP7641938B2 (ja) 相同組換え欠損を評価するための方法および材料
JP7680995B2 (ja) 相同組換え欠損を評価するための方法および材料
WO2017165270A1 (en) Homologous recombination deficiency to predict neoadjuvant chemotherapy necessity in bladder cancer
TWI861616B (zh) 用於評估乳癌亞型中同源重組缺陷之方法及材料
HK40098329A (en) Methods and materials for assessing homologous recombination deficiency
HK40098329B (en) Methods and materials for assessing homologous recombination deficiency
NZ712663B2 (en) Methods and materials for assessing homologous recombination deficiency

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20160415

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160415

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170213

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170213

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20171221

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180131

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180320

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180727

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190426

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20190514

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190731

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190806

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20191108

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20191126

R150 Certificate of patent or registration of utility model

Ref document number: 6625045

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250